Immune Therapy for Cancer

被引:500
作者
Dougan, Michael [1 ]
Dranoff, Glenn
机构
[1] Brigham & Womens Hosp, Dept Med Oncol, Boston, MA 02115 USA
关键词
monoclonal (antibody); inflammation; vaccine; adjuvants; immunotherapy; REGULATORY T-CELLS; COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; BACILLUS-CALMETTE-GUERIN; TUMOR-NECROSIS-FACTOR; PHASE-III TRIAL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LYMPHOCYTE-ASSOCIATED ANTIGEN-4; HELICOBACTER-PYLORI INFECTION; METASTATIC BREAST-CANCER;
D O I
10.1146/annurev.immunol.021908.132544
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Over the past decade, immune therapy has become a standard treatment for a variety of cancers. Monoclonal antibodies, immune adjuvants, and vaccines against oncogenic viruses are now well-established cancer therapies. Immune modulation is a principal element of supportive care for many high-dose chemotherapy regimens. In addition, immune activation is now appreciated as central to the therapeutic mechanism of bone marrow transplantation for hematologic malignancies. Advances in our understanding of the molecular interactions between tumors and the immune system have led to many novel investigational therapies and continue to inform efforts for devising more potent therapeutics. Novel approaches to immune-based cancer treatment strive to augment antitumor immune responses by expanding tumor-reactive T cells, providing exogenous immune-activating stimuli, and antagonizing regulatory pathways that induce immune tolerance. The future of immune therapy for cancer is likely to combine many of these approaches to generate more effective treatments.
引用
收藏
页码:83 / 117
页数:35
相关论文
共 239 条
[1]   HIGH-DOSE METHOTREXATE - A CRITICAL REAPPRAISAL [J].
ACKLAND, SP ;
SCHILSKY, RL .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (12) :2017-2031
[2]   Monoclonal antibody therapy of cancer [J].
Adams, GP ;
Weiner, LM .
NATURE BIOTECHNOLOGY, 2005, 23 (09) :1147-1157
[3]   Cancer vaccines for established cancer: how to make them better? [J].
Andrews, Daniel M. ;
Maraskovsky, Eugene ;
Smyth, Mark J. .
IMMUNOLOGICAL REVIEWS, 2008, 222 :242-255
[4]  
[Anonymous], 2000, COCHRANE DB SYST REV
[5]  
[Anonymous], 2006, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol, DOI DOI 10.1200/JCO.2006.05.9964
[6]   Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].
Apetoh, Lionel ;
Ghiringhelli, Francois ;
Tesniere, Antoine ;
Obeid, Michel ;
Ortiz, Carla ;
Criollo, Alfredo ;
Mignot, Gregoire ;
Maiuri, M. Chiara ;
Ullrich, Evelyn ;
Saulnier, Patrick ;
Yang, Huan ;
Amigorena, Sebastian ;
Ryffel, Bernard ;
Barrat, Franck J. ;
Saftig, Paul ;
Levi, Francis ;
Lidereau, Rosette ;
Nogues, Catherine ;
Mira, Jean-Paul ;
Chompret, Agnes ;
Joulin, Virginie ;
Clavel-Chapelon, Francoise ;
Bourhis, Jean ;
Andre, Fabrice ;
Delaloge, Suzette ;
Tursz, Thomas ;
Kroemer, Guido ;
Zitvogel, Laurence .
NATURE MEDICINE, 2007, 13 (09) :1050-1059
[7]   Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming [J].
Atanackovic, Djordje ;
Altorki, Nasser K. ;
Cao, Yanran ;
Ritter, Erika ;
Ferrara, Cathy A. ;
Ritter, Gerd ;
Hoffman, Eric W. ;
Bokemeyer, Carsten ;
Old, Lloyd J. ;
Gnjatic, Sacha .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (05) :1650-1655
[8]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[9]   Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype [J].
Aversa, F ;
Tabilio, A ;
Velardi, A ;
Cunningham, I ;
Terenzi, A ;
Falzetti, F ;
Ruggeri, L ;
Barbabietola, G ;
Aristei, C ;
Latini, P ;
Reisner, Y ;
Martelli, MF .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (17) :1186-1193
[10]   Cellular immune response to HTLV-1 [J].
Bangham, CRM ;
Osame, M .
ONCOGENE, 2005, 24 (39) :6035-6046